Unlock the Editor’s Digest free of charge
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
Novo Nordisk’s new injectable weight problems drug has the potential to ship greater weight reduction than each of the present market blockbusters, an early stage trial has discovered.
In newly-published knowledge, individuals within the trial of injectable amycretin misplaced a mean of 24.3 per cent of their physique weight on the best dose, in contrast with 1.1 per cent for these on a placebo.
The outcomes come because the Danish pharma group races rival Eli Lilly to secure the best successor to the present finest sellers — Lilly’s Zepbound and Novo’s Wegovy, which respectively trigger common weight lack of 22.5 and 15 per cent.
In accordance with one other early-stage trial additionally printed in medical journal The Lancet on Saturday, a pill model of amycretin brought about common weight lack of 13.1 per cent on the best dose, in contrast with 1.2 per cent for the placebo.
Amycretin combines semaglutide, the lively ingredient in Novo’s Wegovy and Ozempic, with amylin, a hormone that promotes a sense of fullness. Novo stated it might pursue additional trials of each the oral and the injectable model of the drug.
Within the first-phase trial of the amycretin capsule, individuals’ weight reduction didn’t plateau by the top of the 12 weeks, so in an extended trial or actual life setting, they may lose extra.
Martin Lange, Novo Nordisk government vice-president of growth, stated he believes the oral model of the drug might ship related weight reduction to the injectable model, if sufferers take it for longer.
He added that amycretin appears to have “substantial weight reduction potential”, bolstering Novo’s portfolio of anti-obesity medicine. Evan Seigerman, an analyst at BMO Capital Markets, stated amycretin seems to be “promising”.
Novo is making an attempt to persuade traders that its pipeline can compete with Lilly’s, after a disappointing lead to trials of its new CagriSema obesity medication sent its shares tumbling late last year. Extra in depth knowledge on CagriSema can be offered on Sunday on the American Diabetes Affiliation convention.
Shares in Novo have fallen greater than 50 per cent previously yr, as traders fearful it was dropping its result in Lilly’s Zepbound and Mounjaro, and questioned if its pipeline was nearly as good as its rival’s. Final month, the corporate introduced it might search for a replacement for its chief government Lars Fruergaard Jørgensen.
Analysts are optimistic about Lilly’s orforglipron, one other anti-obesity capsule, which brought about common weight lack of 14.7 per cent on the highest dose over 36 weeks, based on a section 2 examine printed in 2023. The outcomes of a newer section 3 trial in diabetic sufferers pushed Lilly’s shares up more than 15 per cent.
Novo Nordisk has already submitted an software for the approval of an oral model of Wegovy to the US drug regulator. That was based mostly on trial knowledge that confirmed sufferers taking the capsule achieved a mean of 16.6 per cent weight reduction over 64 weeks.
